Drug and diagnostic firm partners are working with FDA and cancer research groups to standardize analytical and clinical performance reviews of companion diagnostics for the new drug class of PD-1 and PD-L1 inhibitors. A draft blueprint proposal
developed by representatives of drug and device companies was unveiled March 24 to address the matter, specifically for the non-small...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?